Suppr超能文献

诺南综合征中 14-3-3 与 C-RAF 结合能力受损表明在 Ras 信号转导增加的疾病中存在新的治疗方法。

Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling.

机构信息

Chemical Genomics Centre of the Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany.

出版信息

Mol Cell Biol. 2010 Oct;30(19):4698-711. doi: 10.1128/MCB.01636-09. Epub 2010 Aug 2.

Abstract

The Ras-RAF-mitogen-activated protein kinase (Ras-RAF-MAPK) pathway is overactive in many cancers and in some developmental disorders. In one of those disorders, namely, Noonan syndrome, nine activating C-RAF mutations cluster around Ser(259), a regulatory site for inhibition by 14-3-3 proteins. We show that these mutations impair binding of 14-3-3 proteins to C-RAF and alter its subcellular localization by promoting Ras-mediated plasma membrane recruitment of C-RAF. By presenting biophysical binding data, the 14-3-3/C-RAFpS(259) crystal structure, and cellular analyses, we indicate a mechanistic link between a well-described human developmental disorder and the impairment of a 14-3-3/target protein interaction. As a broader implication of these findings, modulating the C-RAFSer(259)/14-3-3 protein-protein interaction with a stabilizing small molecule may yield a novel potential approach for treatment of diseases resulting from an overactive Ras-RAF-MAPK pathway.

摘要

Ras-RAF-丝裂原活化蛋白激酶(Ras-RAF-MAPK)通路在许多癌症和一些发育障碍中过度活跃。在其中一种疾病,即诺南综合征中,九个激活的 C-RAF 突变聚集在 Ser(259)周围,Ser(259)是受 14-3-3 蛋白抑制的调节位点。我们表明,这些突变会损害 14-3-3 蛋白与 C-RAF 的结合,并通过促进 Ras 介导的 C-RAF 向质膜募集来改变其细胞内定位。通过提供生物物理结合数据、14-3-3/C-RAFpS(259)晶体结构和细胞分析,我们表明了一种机制联系,即将描述的人类发育障碍与 14-3-3/靶蛋白相互作用的损害联系起来。作为这些发现的更广泛意义,用稳定的小分子调节 C-RAFSer(259)/14-3-3 蛋白-蛋白相互作用可能为治疗由于 Ras-RAF-MAPK 通路过度活跃而导致的疾病提供一种新的潜在方法。

相似文献

1
Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling.
Mol Cell Biol. 2010 Oct;30(19):4698-711. doi: 10.1128/MCB.01636-09. Epub 2010 Aug 2.
2
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
Nat Genet. 2007 Aug;39(8):1007-12. doi: 10.1038/ng2073. Epub 2007 Jul 1.
3
Structural determinants of Ras-Raf interaction analyzed in live cells.
Mol Biol Cell. 2002 Jul;13(7):2323-33. doi: 10.1091/mbc.e02-01-0019.
5
14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity.
Mol Cell Biol. 2002 Jul;22(14):4984-96. doi: 10.1128/MCB.22.14.4984-4996.2002.
6
Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
Expert Rev Mol Med. 2008 Dec 9;10:e37. doi: 10.1017/S1462399408000902.
7
Cell type-specific importance of ras-c-raf complex association rate constants for MAPK signaling.
Sci Signal. 2009 Jul 28;2(81):ra38. doi: 10.1126/scisignal.2000397.
8
Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration.
Nat Cell Biol. 2005 Aug;7(8):837-43. doi: 10.1038/ncb1283. Epub 2005 Jul 24.
9
Synergistic binding of the phosphorylated S233- and S259-binding sites of C-RAF to one 14-3-3ζ dimer.
J Mol Biol. 2012 Nov 2;423(4):486-95. doi: 10.1016/j.jmb.2012.08.009. Epub 2012 Aug 24.
10
Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade.
Recent Prog Horm Res. 2001;56:127-55. doi: 10.1210/rp.56.1.127.

引用本文的文献

1
Identifying 14-3-3 interactome binding sites with deep learning.
Digit Discov. 2025 Aug 8. doi: 10.1039/d5dd00132c.
3
Fragment-Based Interrogation of the 14-3-3/TAZ Protein-Protein Interaction.
Biochemistry. 2024 Sep 3;63(17):2196-2206. doi: 10.1021/acs.biochem.4c00248. Epub 2024 Aug 22.
4
Development of a NanoBRET assay for evaluation of 14-3-3σ molecular glues.
SLAS Discov. 2024 Jul;29(5):100165. doi: 10.1016/j.slasd.2024.100165. Epub 2024 May 24.
5
14-3-3 Protein-Protein Interactions: From Mechanistic Understanding to Their Small-Molecule Stabilization.
Chembiochem. 2024 Jul 15;25(14):e202400214. doi: 10.1002/cbic.202400214. Epub 2024 Jun 24.
6
Regulation of RAF family kinases: new insights from recent structural and biochemical studies.
Biochem Soc Trans. 2024 Jun 26;52(3):1061-1069. doi: 10.1042/BST20230552.
7
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.
Nat Rev Cancer. 2024 Feb;24(2):105-122. doi: 10.1038/s41568-023-00650-x. Epub 2024 Jan 9.
10
A Systematic Approach to the Discovery of Protein-Protein Interaction Stabilizers.
ACS Cent Sci. 2023 Apr 18;9(5):937-946. doi: 10.1021/acscentsci.2c01449. eCollection 2023 May 24.

本文引用的文献

1
Identification and structure of small-molecule stabilizers of 14-3-3 protein-protein interactions.
Angew Chem Int Ed Engl. 2010 Jun 1;49(24):4129-32. doi: 10.1002/anie.200907203.
2
Structure of the p53 C-terminus bound to 14-3-3: implications for stabilization of the p53 tetramer.
FEBS Lett. 2010 Apr 16;584(8):1443-8. doi: 10.1016/j.febslet.2010.02.065. Epub 2010 Mar 3.
3
Mechanistic differences in the transcriptional activation of p53 by 14-3-3 isoforms.
Nucleic Acids Res. 2010 Jan;38(3):893-906. doi: 10.1093/nar/gkp1041. Epub 2009 Nov 20.
4
Cell type-specific importance of ras-c-raf complex association rate constants for MAPK signaling.
Sci Signal. 2009 Jul 28;2(81):ra38. doi: 10.1126/scisignal.2000397.
5
The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch.
Cell Signal. 2009 Nov;21(11):1645-51. doi: 10.1016/j.cellsig.2009.07.001. Epub 2009 Jul 10.
8
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
Nat Genet. 2007 Aug;39(8):1007-12. doi: 10.1038/ng2073. Epub 2007 Jul 1.
9
Germline gain-of-function mutations in RAF1 cause Noonan syndrome.
Nat Genet. 2007 Aug;39(8):1013-7. doi: 10.1038/ng2078. Epub 2007 Jul 1.
10
Hyperactive Ras in developmental disorders and cancer.
Nat Rev Cancer. 2007 Apr;7(4):295-308. doi: 10.1038/nrc2109.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验